Kling Biotherapeutics to Present Discoveries on its Primary B-Cell Screening Platform at the ESMO Targeted Anticancer Therapies Congress
Published on 08/07/2025 at 18:07 | prnewswire.co.uk
under identifier NCT05501821.
About ESMO
ESMO's core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.
View original content:https://www.prnewswire.co.uk/news-releases/kling-biotherapeutics-to-present-discoveries-on-its-primary-b-cell-screening-platform-at-the-esmo-targeted-anticancer-therapies-congress-302067643.html
en | boerse | 67948837 |
